Breast cancer metastatic+1
RecruitingStudy on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer
Study on the Effectiveness of Trastuzumab Deruxtecan in Patients with HER2-Positive Oligometastatic Breast Cancer
- Disease:Breast cancer metastaticHER2 positive breast cancer
- Substances:Trastuzumab Deruxtecan
Italy- Participants:18–64 years · 65+ years
- Substances:Trastuzumab Deruxtecan
- Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting










